These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 17270637)

  • 21. Salvage chemotherapy with docetaxel and epirubicin for advanced/metastatic gastric cancer.
    Lim JY; Cho JY; Paik YH; Lee DK; Lee SI; Park HJ; Lee SJ; Lee KS; Yoon DS; Choi SH
    Oncology; 2007; 73(1-2):2-8. PubMed ID: 18332648
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Docetaxel plus prednisolone for the treatment of metastatic hormone-refractory prostate cancer: a multicenter Phase II trial in Japan.
    Naito S; Tsukamoto T; Koga H; Harabayashi T; Sumiyoshi Y; Hoshi S; Akaza H
    Jpn J Clin Oncol; 2008 May; 38(5):365-72. PubMed ID: 18417502
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A weekly schedule of docetaxel for metastatic hormone-refractory prostate cancer.
    Ferrero JM; Foa C; Thezenas S; Ronchin P; Peyrade F; Valenza B; Lesbats G; Garnier G; Boublil JL; Tchiknavorian X; Chevallier D; Amiel J
    Oncology; 2004; 66(4):281-7. PubMed ID: 15218295
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of prognostic factors and efficacy in a phase-II study with docetaxel and estramustine for advanced hormone refractory prostate cancer.
    Nelius T; Reiher F; Lindenmeir T; Klatte T; Rau O; Burandt J; Filleur S; Allhoff EP
    Onkologie; 2005 Nov; 28(11):573-8. PubMed ID: 16249643
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is it reasonable to consider second-line chemotherapy in patients with hormone-refractory prostate cancer?
    Odrazka K; Vaculikova M; Dolezel M; Petera J; Moravek P; Prosvic P; Zoul Z; Vosmik M; Dolezal J; Simakova E
    Oncol Rep; 2005 Oct; 14(4):1077-81. PubMed ID: 16142375
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High dose pulse calcitriol, docetaxel and estramustine for androgen independent prostate cancer: a phase I/II study.
    Tiffany NM; Ryan CW; Garzotto M; Wersinger EM; Beer TM
    J Urol; 2005 Sep; 174(3):888-92. PubMed ID: 16093981
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination chemotherapy with docetaxel, vinorelbine and estramustine phosphate in metastatic androgen-resistant prostate cancer: a single institution experience.
    Pectasides D; Pectasides E; Papaxoinis G; Koumarianou A; Psyrri A; Xiros N; Tountas N; Kamposioras K; Papatsibas G; Floros T; Gouveris P; Karageorgopoulou S; Economopoulos T
    Anticancer Res; 2009 Feb; 29(2):769-75. PubMed ID: 19331234
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase I study of bi-weekly docetaxel for recurrent or advanced gastric cancer patients whose disease progressed by prior chemotherapy.
    Kimura Y; Yano H; Taniguchi H; Iwazawa T; Danno K; Kagara N; Kanoh T; Ohnishi T; Tono T; Nakano Y; Monden T; Imaoka S
    Jpn J Clin Oncol; 2011 Jun; 41(6):747-51. PubMed ID: 21498408
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intermittent docetaxel chemotherapy in patients with castrate-resistant prostate cancer.
    Mountzios I; Bournakis E; Efstathiou E; Varkaris A; Wen S; Chrisofos M; Deliveliotis C; Alamanis C; Anastasiou I; Constantinides C; Karadimou A; Tsiatas M; Papadimitriou C; Bamias A; Dimopoulos MA
    Urology; 2011 Mar; 77(3):682-7. PubMed ID: 21256546
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of docetaxel in patients with hormone-dependent prostate-specific antigen progression after local therapy for prostate cancer.
    Goodin S; Medina P; Capanna T; Shih WJ; Abraham S; Winnie J; Doyle-Lindrud S; Todd M; DiPaola RS
    J Clin Oncol; 2005 May; 23(15):3352-7. PubMed ID: 15738531
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer.
    Dreicer R; Petrylak D; Agus D; Webb I; Roth B
    Clin Cancer Res; 2007 Feb; 13(4):1208-15. PubMed ID: 17317831
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase-II study of docetaxel, estramustine phosphate, and carboplatin in patients with hormone-refractory prostate cancer.
    Kikuno N; Urakami S; Nakamura S; Hiraoka T; Hyuga T; Arichi N; Wake K; Sumura M; Yoneda T; Kishi H; Shigeno K; Shiina H; Igawa M
    Eur Urol; 2007 May; 51(5):1252-8. PubMed ID: 17208356
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination chemotherapy with docetaxel, estramustine and suramin for hormone refractory prostate cancer.
    Safarinejad MR
    Urol Oncol; 2005; 23(2):93-101. PubMed ID: 15869993
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of docetaxel plus estramustine in the treatment of patients with hormone-refractory prostate cancer.
    Matsumoto A; Inoue A; Yokoi S; Nozumi K; Miyazaki K; Hosoki S; Nagata M; Yamaguchi K
    Int J Urol; 2009 Aug; 16(8):687-91. PubMed ID: 19602005
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase I/II dose-escalation study of exisulind and docetaxel in patients with hormone-refractory prostate cancer.
    Ryan CW; Stadler WM; Vogelzang NJ
    BJU Int; 2005 May; 95(7):963-8. PubMed ID: 15839914
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer.
    Oh WK; Hagmann E; Manola J; George DJ; Gilligan TD; Jacobson JO; Smith MR; Kaufman DS; Kantoff PW
    Clin Cancer Res; 2005 Jan; 11(1):284-9. PubMed ID: 15671557
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Salvage therapy with oral metronomic cyclophosphamide and methotrexate for castration-refractory metastatic adenocarcinoma of the prostate resistant to docetaxel.
    Gebbia V; Serretta V; Borsellino N; Valerio MR;
    Urology; 2011 Nov; 78(5):1125-30. PubMed ID: 22054386
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Docetaxel in combination with prednisolone for hormone refractory prostate cancer.
    Ide H; Kikuchi E; Kono H; Nagata H; Miyajima A; Nakagawa K; Ohigashi T; Nakashima J; Oya M
    Jpn J Clin Oncol; 2010 Jan; 40(1):79-84. PubMed ID: 19837689
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination chemotherapy with weekly docetaxel and estramustine for hormone refractory prostate cancer in Japanese patients.
    Takenaka A; Yamada Y; Kurahashi T; Soga H; Miyake H; Fujisawa M
    Int J Urol; 2008 Jan; 15(1):106-9. PubMed ID: 18184188
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Weekly chemotherapeutic regimen in metastatic prostate cancer.
    Burk K
    Prog Clin Biol Res; 1990; 350():187-200. PubMed ID: 2201043
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.